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Summary
Background—Treatment of breast cancer with aromatase inhibitors is associated with damage 
to bones. NCIC CTG MA.27 was an open-label, phase 3, randomised controlled trial in which 
women with breast cancer were assigned to one of two adjuvant oral aromatase inhibitors—
exemestane or anastrozole. We postulated that exemestane—a mildly androgenic steroid—might 
have a less detrimental effect on bone than non-steroidal anastrozole. In this companion study to 
MA.27, we compared changes in bone mineral density (BMD) in the lumbar spine and total hip 
between patients treated with exemestane and patients treated with anastrozole.
Methods—In MA.27, postmenopausal women with early stage hormone (oestrogen) receptor-
positive invasive breast cancer were randomly assigned to exemestane 25 mg versus anastrozole 1 
mg, daily. MA.27B recruited two groups of women from MA.27: those with BMD T-scores of –
2·0 or more (up to 2 SDs below sex-matched, young adult mean) and those with at least one T-
score (hip or spine) less than –2·0. Both groups received vitamin D and calcium; those with 
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baseline T-scores of less than –2·0 also received bisphosphonates. The primary endpoints were 
percent change of BMD at 2 years in lumbar spine and total hip for both groups. We analysed 
patients according to which aromatase inhibitor and T-score groups they were allocated to but 
BMD assessments ceased if patients deviated from protocol. This study is registered with 
ClinicalTrials.gov, NCT00354302.
Findings—Between April 24, 2006, and May 30, 2008, 300 patients with baseline T-scores of –
2·0 or more were accrued (147 allocated exemestane, 153 anastrozole); and 197 patients with 
baseline T-scores of less than –2·0 (101 exemestane, 96 anastrozole). For patients with T-scores 
greater than –2·0 at baseline, mean change of bone mineral density in the spine at 2 years did not 
differ significantly between patients taking exemestane and patients taking anastrozole (−0·92%, 
95% CI −2·35 to 0·50 vs −2·39%, 95% CI −3·77 to –1·01; p=0·08). Respective mean loss in the 
hip was −1·93% (95% CI −2·93 to –0·93) versus −2·71% (95% CI −4·32 to –1·11; p=0·10). 
Likewise for those who started with T-scores of less than –2·0, mean change of spine bone mineral 
density at 2 years did not differ significantly between the exemestane and anastrozole treatment 
groups (2·11%, 95% CI −0·84 to 5·06 vs 3·72%, 95% CI 1·54 to 5·89; p=0·26), nor did hip bone 
mineral density (2·09%, 95% CI −1·45 to 5·63 vs 0·0%, 95% CI −3·67 to 3·66; p=0·28). Patients 
with baseline T-score of –2·0 or more taking exemestane had two fragility fractures and two other 
fractures, those taking anastrozole had three fragility fractures and five other fractures. For 
patients who had baseline T-scores of less than –2·0 taking exemestane, one had a fragility 
fracture and four had other fractures, whereas those taking anastrozole had five fragility fractures 
and one other fracture.
Interpretation—Our results demonstrate that adjuvant treatment with aromatase inhibitors can 
be considered for breast cancer patients who have T-scores less than –2·0.
Funding—Canadian Cancer Society Research Institute, Pfizer, Canadian Institutes of Health 
Research.
Introduction
Aromatase inhibitors have largely replaced tamoxifen as adjuvant endocrine treatment for 
postmenopausal women with hormone-receptor-positive breast cancer.1–3 Two classes of 
aromatase inhibitors are prescribed at present: non-steroidal (anastrozole and letrozole), and 
steroidal (exemestane). Aromatase inhibitors decrease circulating oestrogen concentrations 
in postmenopausal women,4,5 resulting in accelerated bone loss, decreased bone mineral 
density, and increased risk of clinical fractures.6 Exemestane—with its unique androgenic 
structure—results in less bone loss according to studies of animals and man.7,8
Bone loss can be treated or prevented with bisphosphonates, which inhibit osteoclast-
mediated bone resorption, and thereby increase bone mineral density, reducing the risk of 
fracture.9,10 Bisphosphonates11–14 and denosumab15 can counteract bone loss of women 
treated with aromatase inhibitors; however, most breast cancer trials excluded women with 
osteoporosis at baseline.11
NCIC CTG MA.27 was a randomised control trial16 of 7576 postmenopausal women 
assigned to adjuvant exemestane or anastrozole, which showed no significant difference for 
event-free survival between treatments. Patients in the exemestane group reported fewer 
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new cases of osteopenia or osteoporosis than in the anastrozole group (1171 vs 1304; 
p<0·001). We did a companion study to answer two questions about bone health in these 
patients: first, did changes of bone mineral density differ between adjuvant anastrozole and 
adjuvant exemestane groups? And second, for women with osteopenia or osteoporosis, did 
bisphosphonate treatment restore bone mineral density equally in each treatment group?
Methods
Study design
The present study (MA.27B) is a companion study to NCIC CTG MA.27, an open-label 
phase 3 randomised controlled trial of the oral drugs exemestane 25 mg versus anastrozole 1 
mg, done at 40 centres in Canada, 363 in the USA, and 43 worldwide through the 
International Breast Cancer Study Group. Treatment was given daily for 5 years as adjuvant 
treatment for postmenopausal patients with early, hormone receptor-positive breast cancer.16 
Patients were randomised at the NCIC CTG central office with dynamic minimisation.17 
Stratification was by lymph node status, adjuvant chemotherapy, and use of celecoxib, 
aspirin 81 mg, and trastuzumab. The primary endpoint was event-free survival. Provision of 
MA.27 trial treatment stopped on Dec 31, 2010.
Enrolment to MA.27B took place after patients discontinued celecoxib (due to reports of 
cardiotoxicity) in MA.27.16 MA.27B was done at nine centres in Canada and 89 in the USA. 
The study included patients who had a dual-energy x-ray absorptiometry scan of acceptable 
quality, done within 25 weeks of randomisation in MA.27. MA.27B included two distinct 
groups of patients from MA.27. The first included those with baseline T-scores for bone 
mineral density of –2·0 or greater (up to two SDs below sex-matched patients younger than 
age 30 years) at the spine and hip (no osteopenia or osteoporosis). These patients could not 
have received any drugs—including bisphosphonates—in the 6 months before registration 
for MA.27B. The second group consisted of patients with at least one T-score less than –2·0, 
who may have started bisphosphonates up to 25 weeks before registration. They were 
permitted to continue the same bisphosphonate treatment. If not started previously, 
bisphosphonate treatment began when these patients were enrolled into MA.27B. The 
bisphosphonate treatment was chosen by the patient and their doctor; we did not analyse 
differences in outcome by type of bisphosphonate. Patients with T-score less than –2·0 had 
to have a creatinine clearance of more than 35 mL/min according to the Cockcroft-Gault 
formula. The cutoff of –2·0 was chosen because it conforms with several clinical guidelines 
recommending bisphosphonate treatment.18
The full protocol is available online. MA.27B was approved by health regulatory authorities 
and participating centres’ institutional review boards. Patients provided written consent.
Procedures
We used dual-energy x-ray absorptiometry densitometers manufactured by Hologic 
(Bedford, MA, USA) or GE Lunar (Madison, WI, USA) to assess bone mineral density of 
the lumbar spine (L1–L4) and hip. Participants in MA.27B were prescribed calcium 1000 
mg and vitamin D 800 IU daily.
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All patients had to have had their 2-year assessments done by Jan 22, 2011. Patients had 
their bone mineral density assessed yearly for 5 years. The study was truncated when the 
core MA.27 trial was closed, so the original intention to assess change of bone mineral 
density at 3 years and 5 years was not possible.
When possible, bone scans were analysed centrally by technologists certified by the 
International Society of Clinical Densitometry. Areal bone mineral densities assessed by 
Lunar intruments were expressed as Hologic equivalents.19 We assessed changes by eye 
when density assessments were presented graphically, which was very rare, although we do 
not have a precise number. We calculated T-scores at baseline, 1 year, and 2 years centrally 
for all patients.
We measured changes in serum markers of bone turnover and bone formation (N-terminal of 
procollagen type 1 propeptide [PINP] and serum N-telopeptide [NTX]) at 6 months and 12 
months compared with baseline. We measured PINP and NTX concentrations from non-
fasting serum samples collected in yellow-top separator tubes, left to sit for 30 min after 
collection, then centrifuged, aliquoted, and frozen at −70°C (appendix p 23). Samples were 
batched and shipped on dry ice to a central laboratory (appendix).
Outcomes
The primary endpoints were percent change of spine and hip bone mineral density from 
baseline to 2 years. Our primary objectives were to assess whether there was a 5% 
difference between T-score groups for the primary endpoint. This analysis included only 
patients assessed at 2 years. Assessments of bone mineral density were stopped with 
discontinuation of MA.27 treatment, or for those patients with baseline T-score of –2·0 or 
more, with prescription of bisphosphonate.
Secondary objectives at 2 years were: percent change by patient of bone mineral density at 1 
year; absolute change by patient of T-score between baseline and 1 year and 2 years; 
treatment group mean percent change of bone mineral density and T-score, between baseline 
and 1 year and 2 years; and clinically relevant changes at 2 years. For patients with baseline 
T-scores of –2·0 or more, clinically relevant changes were the development of T-score of 
less than –2·0 at the spine or hip, or clinical fracture, and for patients with baseline T-scores 
of less than –2·0, they were improvements of 5% or more in bone mineral density from 
baseline, or development of clinical fracture. Fractures were classified as fragility (eg, 
fractures resulting from low or no trauma) or other type.20
Statistical analysis
We estimated the SD of percent change of bone mineral density to be 0·10.21 Four 
comparisons of exemestane and anastrozole treatment assessed whether there was a 5% 
difference for change in bone mineral density: for each group of patients with different 
baseline T-scores, change was compared in spine and in hip. Each primary objective would 
be significant using a Bonferroni adjustment if two-sided p values were 0·0125 or less 
(0·05/4), with power of 0·80. Each T-score group within each treatment group required 89 
patients. We expected 10% of patients to withdraw (missing assessments or loss to follow-
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up) and 5% to drop out by 2 years, for which we needed 102 patients per group; 408 patients 
overall.
Attrition at 2 years was greater than expected so we assessed whether baseline bone mineral 
density was different between those with and those without data for bone mineral density at 
2 years; we also compared bone mineral density at baseline between patients with versus 
those without data at 1 year with a two-sided Student's t tests. We assessed patients who 
started bisphosphonates in the high baseline T-score group and discontinued treatment in the 
low baseline T-score group by baseline and 2-year T-scores from graphs.
We assessed the primary objective with two-sided Student's t tests of individual patient 
change of bone mineral density (g/cm2); patients included in these analyses had bone 
mineral density assessed at both timepoints, although not always at both hip and spine. We 
also compared treatment effects by T-score group, including patients with bone mineral 
density at baseline compared with those with data at 2 years.
We did sensitivity analyses of change by 1 year and 2 years with centrally calculated T-
scores (differences between baseline and one timepoint). We did exploratory generalised 
linear model longitudinal investigations to assess whether hip and spine bone mineral 
density differed over time, by treatment, and whether there was an interaction of time and 
treatment. We used only patients with hip (or spine) bone mineral density assessments at all 
timepoints (baseline, 1 year, and 2 years). We also did an exploratory longitudinal 
assessment with SAS Proc Mixed of all available hip (or spine) bone mineral density 
assessments at all timepoints, adding baseline bone mineral density as an explanatory 
variable.
We analysed patients according to which aromatase inhibitor they were allocated and T-
score at baseline groups but bone mineral density assessments after baseline ceased if 
patients deviated from their protocol-assigned treatment. Such patients were then excluded 
from the subsequent analyses.
We used exact Fisher tests to assess differences in fracture rates at 2 years and clinically 
relevant changes in each T-score group. We used t tests to assess both individual and group 
changes of PINP and NTX. We used SAS (version 9.2) for these analyses.
This study is registered with ClinicalTrials.gov, NCT00354302.
Role of the funding source
MA.27B data were collected, managed, and analysed by NCIC CTG. The trial committee 
decided to publish the results. The sponsor had no role in designing the study or writing the 
report. LES, CRE, and J-AWC had full access to all the data.
Results
Between April 24, 2006, and May 30, 2008, 497 patients were accrued to MA.27B. 300 
patients had baseline T-scores of –2·0 or more, 197 had scores of less than –2·0. 13 patients 
in each T-score group were ineligible (figure 1). All enrolled patients were included in the 
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analyses; ineligible patients were not excluded if they had bone mineral density assessed at 
the protocol-specified times. Baseline patient characteristics (table 1) were similar to those 
of patients in MA.27 (data not shown).16 Characteristics were well balanced between 
treatment groups, within each T-score group. Calcium and vitamin D supplementation was 
maintained by 297 of 300 (99·0%) patients with baseline T-scores of –2·0 or more, and 194 
of 197 (98·5%) with baseline T-scores of less than –2·0. Histograms of spine and hip bone 
mineral density at baseline and 2 years show a fairly symmetrical distribution (appendix pp 
1–8).
Figure 1 shows the number of patients and those with assessable bone mineral density at 
each timepoint according to T-score group and treatment allocation. The post-hoc power for 
the primary analysis was 0·65–0·72. Baseline bone mineral density of patients who had data 
available for 1 year and 2 years was generally not significantly different from those who did 
not have data at 1 year and 2 years (data not shown); the only significant difference was that 
patients with baseline T-score of less than –2·0 taking anastrozole assessed at 2 years had 
significantly lower spine bone mineral density at baseline (p=0·01) than those not assessed 
at 2 years. Plots of matched baseline to 2-year T-scores indicate that only two patients with 
baseline T-scores of –2·0 or more had a reduction in T-score to less than –2·0 and started 
bisphosphonates (appendix pp 9–10). Likewise, only nine women with baseline T-scores of 
less than –2·0 withdrew with 2-year T-scores which persisted to be less than –2·0 (appendix 
pp 11–12).
For patients with baseline T-score of –2·0 or more, we detected no significant difference for 
mean loss of bone mineral density in the hip at 2 years between patients taking exemestane 
(−1·93%, 95% CI −2·93 to –0·93) versus anastrozole (−2·71%, 95% CI −4·32 to –1·11; 
p=0·10; table 2). We report similar results for bone mineral density in the spine (−0·92%, 
95% CI −2·35 to 0·50 vs −2·39%, 95% CI −3·77 to –1·01; p=0·08). Absolute changes of 
individual T-scores were not significantly different between treatment groups (table 3). 
Unmatched group comparisons between timepoints are shown in the appendix (p 13); loss of 
spine bone mineral density was significant for patients taking anastrozole (p=0·05) but not 
those taking exemestane. At 1 year, mean loss of bone mineral density in the hip was 
significantly less for patients taking exemestane versus those taking anastrozole (table 2), 
although again, absolute T-scores did not differ significantly (table 3). Loss of bone mineral 
density in the spine at 1 year did not differ significantly between treatment groups (tables 2 
and 3).
For patients with baseline T-score of less than –2·0, mean change of bone mineral density in 
the spine at 2 years did not differ significantly between exemestane and anastrozole groups 
(2·11%, 95% CI −0·84 to 5·06 vs 3·72%, 95% CI 1·54 to 5·89; p=0·26; table 2). Likewise, 
there was no significant difference between groups for mean bone mineral density in the hip 
(2·09%, 95% CI −1·45 to 5·63 vs 0·00%, 95% CI −3·67 to 3·66; p=0·28; table 2). Individual 
and group changes in spine and hip T-scores were not significantly different between 
treatment groups (table 3; appendix p 15).
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In longitudinal assessments, for patients who had data at all timepoints (baseline, 1 year, and 
2 years; appendix p 14) and patients who had data missing at some timepoints (appendix p 
15), we recorded similar results.
In patients who had a baseline T-score of –2·0 or more, spine bone mineral density for each 
patient decreased at 2 years, with less decrease for patients allocated to exemestane (figure 
2A, appendix p 14); we found no significant interaction between treatment and time (p=0·21 
for patients with complete data; p=0·10 for those with incomplete data). Hip bone mineral 
density for these patients decreased significantly by 2 years (figure 2A; p<0·0001, for 
patients with both complete and incomplete data; appendix p 14), with no significant 
treatment difference (appendix p 14), and no significant interaction of treatment and time 
(p=0·58 for patients with complete data; p=0·26 for those with incomplete data). Baseline 
hip and spine bone mineral density significantly affected the results (p<0·0001).
For patients with baseline T-scores of less than –2·0, individual patient spine bone mineral 
density increased significantly by 2 years (figure 2B; p<0·0001, for both those with 
complete and those with incomplete data; appendix p 14); there was no significant treatment 
difference or interaction between treatment and time (appendix pp 9–12). Hip bone mineral 
density in these patients changed significantly by 2 years for patients with complete data 
(figure 2B), but not for those with incomplete data (appendix p 14). Treatment groups did 
not differ significantly and we detected no interaction of treatment and time (p=0·51 for 
patients with complete data; p=0·65 for patients with incomplete data; appendix p 14). As 
for those with high baseline T-scores, baseline hip and spine bone mineral density 
significantly affected the results for those with low baseline T-scores (p<0·0001; appendix p 
14).
In patients with baseline T-scores of –2·0 or more, fewer women who took exemestane 
(20/138, 14·5%) than took anastrozole (29/141, 20·6%) started bisphosphonate treatment by 
2 years (p=0·21). However, six women in each treatment group developed hip T-score of 
less than –2·0 (p=1·00; appendix p 16), while 13 women taking exemestane and seven taking 
anastrozole had a similar reduction in spine T-score (p=0·34; appendix p 16). For patients 
with baseline T-scores of less than –2·0, 16 women taking exemestane and nine taking 
anastrozole had clinically relevant hip changes (≥5% improvement of bone mineral density; 
p=0·26; appendix p 16), while 25 women taking exemestane and 27 taking anastrozole had 
similar improvements of spine bone mineral density (p=0·46; appendix p 16).
For patients with baseline T-scores of –2·0 or more, two fragility fractures occurred in the 
exemestane group versus three in the anastrozole group. For those with low baseline T-
scores, one versus five fragility fractures occurred. The proportions of other fractures did not 
differ significantly between treatment groups in either T-score group (appendix p 17).
Markers of bone turnover were assessed for 401 patients at baseline, 328 at 6 months, and 
290 at 1 year. For patients with both high T-score and low T-score, changes in markers of 
bone turnover in one treatment group did not differ significantly from changes in the other 
treatment group (appendix p 18), although both markers increased slightly in those patients 
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with baseline T-scores of –2·0 or more (table 4, appendix p 18) and decreased in those with 
T-scores of less than –2·0 at baseline (table 4, appendix p 18).
Discussion
The effects of aromatase inhibitors on bone mineral density at 2 years did not differ 
significantly between patients treated with exemestane and those treated with anastrozole. 
Although we noted less loss of bone mineral density in the hip for patients with baseline T-
scores of –2·0 or more taking exemestane after 1 year, this benefit was not maintained. 
However, this finding accords with the fewer self-reported diagnoses of osteopenia and 
osteoporosis by patients in the exemestane group than in the anastrozole group in MA.27.16 
Previous studies22,23 of exemestane showed that bone mineral density fell during the first 
year and stabilised thereafter (panel).
We noted less of a decrease in bone mineral density—for both spine and hip—in patients 
with baseline T-scores of –2·0 or more taking exemestane than that reported in other trials of 
exemestane.25,26 For example, in the Intergroup Exemestane Study,25 median change of 
bone mineral density at 2 years was −3·93% in the hip and −2·88% in the spine. Patients 
treated in the TEAM trial had mean change of bone mineral density of −3·5% at 2 years.26 
Our favourable results could be partly attributed to mandatory vitamin D and calcium 
supplementation, which was maintained by almost all patients; this hypothesis is supported 
by a meta-analysis showing that calcium and vitamin D can prevent bone loss for women 
aged 50 years and older.27 We have reported results of a trial of exemestane for prevention 
of breast cancer,28 which showed changes in bone mineral density at 2 years of −1·8% for 
hip and −2·4% for spine. Exemestane caused decreases of cortical thickness at the distal 
radius and distal tibia despite mandatory vitamin D and calcium supplementation. The large 
ATAC bone substudy29 showed that bone mineral density increases after cessation of 
aromatase inhibitors and increased fracture risk does not persist in the long term, suggesting 
that bone changes induced by aromatase inhibitors are largely reversible with cessation of 
treatment and normalisation of menopausal oestrogen concentrations.
The different use of bisphosphonates in our study for the groups of women was based on 
their baseline bone mineral assessment.30 General clinical practice is to prescribe 
bisphosphonates for patients with T-scores of less than –2·0, but not for those with a T-score 
of –2·0 or more: our study conforms with this practice. The differences in effects of bone 
mineral density between treatment groups might have been attenuated by greater than 
expected attrition of patients assigned to take bisphosphonates, which reduced the power of 
the analysis, and the fewer patients with a baseline T-score of –2·0 or more taking 
exemestane who started bisphosphonates than those taking anastrozole.
The role of oral bisphosphonates in conjunction with aromatase inhibitors has been tested in 
several trials.12–14,24 Women who received oral bisphosphonates had either stabilised or 
increased bone mineral density at 2 years12,14 and 3 years.24 None of the trials of 
intravenous bisphosphonates included women with T-scores of less than –2·0 when starting 
aromatase inhibitor treatment.11 MA.27B is the largest prospective bone study to assess the 
role of oral bisphosphonate treatment for women with T-scores less than –2·0 with 
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concomitant aromatase inhibitors. We showed that—despite the likelihood of strong 
oestrogen suppression during treatment with aromatase inhibitors—bisphosphonates 
prevented aromatase inhibitor-induced bone loss. This observation accords with other 
studies that have shown preservation or improvement of bone mineral density for patients 
receiving aromatase inhibitor treatment and concurrent bisphophonates or denosumab. This 
result underscores that osteoporotic patients with breast cancer should not be denied the 
opportunity offered by aromatase inhibitors for treatment of breast cancer.
For clinicians concerned about the effects of adjuvant aromatase inhibitors for osteoporotic 
patients with breast cancer, our results show that osteoporosis can be managed with 
concomitant initiation of oral bisphosphonates and supplementation with calcium and 
vitamin D. Clinical fractures were rare. We found no difference in bone turnover biomarkers 
between the two aromatase inhibitors. Similarly, a randomised trial of healthy volunteers 
showed that aromatase inhibitors have similar effects on bone turnover.31
Our study has some limitations. Patients were predominantly white; however, two studies 
have shown that the effects of aromatase inhibitors on bone loss for Japanese women are 
similar to those for white women.32,33 We did not record detailed information about 
patients’ exercise habits, smoking or family bone health history, or vitamin D and 
parathormone concentrations, which might affect changes in bone mineral density over time. 
The doses of vitamin D used in MA.27B were lower than would be used at present. Samples 
of markers of bone turnover were not collected while fasting, which might have affected 
variability of the results. We did not record morphometric data for the reported fractures.
The analyses were intention to treat for patients who remained on protocol treatment. Full 
intention-to-treat analyses were not possible because data for bone mineral density were not 
available after baseline for patients who went off protocol treatment. We addressed this 
shortcoming by testing for differences by treatment group at baseline for patients who did or 
did not have bone mineral density assessments at 2 years or 1 year. Only one of 16 tests 
indicated a significant difference. Furthermore, we did all tests with use of individual change 
(matched comparisons where patients had bone mineral density assessed at both timepoints) 
and group change (grouped patient data with any patient bone mineral density available at 
either timepoint). The latter analyses used intention-to-treat population data for bone mineral 
density.
Attrition was greater than expected, which led to fewer than the 89 patients planned for each 
treatment group of the primary objectives. For patients with baseline T-scores of –2·0 or 
more, the primary results were not significant with little possibility that they would have 
been significant had we enrolled as many patients as planned—those not assessed at 2 years 
had similar baseline bone mineral density to those who were assessed. For patients with less 
than –2·0 at baseline, with p values of 0·28 for hip and 0·26 for spine bone mineral density, 
it is also unlikely that differences would have been significant had enrolment targets been 
met. How the lower baseline spine bone mineral density for patients taking anastrozole than 
those taking exemestane might have affected spine outcome is unclear.
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MA.27B was originally planned to have assessments of bone mineral density at 3 years and 
5 years. The study was truncated when the core MA.27 trial was closed; however, MA.27B 
had uniform 2-year follow-up to meet the primary objectives. This follow-up does not 
enable us to assess long-term effects of aromatase inhibitors on clinical fracture risk or bone 
health.
Our study provides evidence related to several clinically relevant issues. In women with T-
scores of –2·0 or greater, ensuring adequate vitamin D and calcium supplementation is 
advisable for optimal bone health management. Our findings for women with T-scores less 
than –2·0 are of particular clinical relevance, since low T-score is a common reason to 
withhold treatment with aromatase inhibitors, particularly for older women. Our data show 
that in this often osteopenic or osteoporotic group, bisphosphonates can preserve or improve 
bone mineral density. Bone health should be taken into account when planning adjuvant 
endocrine treatment, but our results show that at least short-term effects of aromatase 
inhibitors on bone can be successfully managed. Our findings support the present guidelines 
of monitoring bone mineral density of women receiving aromatase inhibitors and managing 
bone loss.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Panel: Research in context
Systematic review
We searched PubMed and the Cochrane Database of Systematic Reviews with the terms 
“breast cancer”, “aromatase inhibitors”, “exemestane”, “anastrozole”, “letrozole”, 
“bone”, “bone mineral density”, “bone turnover markers”, “osteoporosis”, “fractures”, 
and “bisphosphonates”. We identified substudies of bone from all major trials of 
aromatase inhibitors for adjuvant breast cancer treatment, which showed that aromatase 
inhibitors are associated with increased risk of bone loss.1–3 We found two preclinical 
studies6 and a randomised trial of healthy postmenopausal women7 suggesting that 
exemestane (a steroidal aromatase inhibitor) could cause less bone loss than other 
aromatase inhibitors. MA.27 directly compared two aromatase inhibitors in 
postmenopausal patients with breast cancer, and reported fewer cases of osteopenia or 
osteoporosis for patients taking exemestane than those taking anastrozole.16 We 
identified four trials12–14,24 of oral bisphosphonates for women with baseline 
osteoporosis starting an aromatase inhibitor.
Interpretation
We designed a bone substudy to directly compare the effect of two aromatase inhibitors 
(exemestane and anastrozole) in postmenopausal women with breast cancer enrolled in 
the MA.27 trial. We also assessed the role of oral bisphosphonate treatment for women 
with T-scores less than –2·0 with concomitant administration of an aromatase inhibitor. 
Both aromatase inhibitors had a similar effect on hip and spine bone mineral density at 2 
years for patients with both T-scores of –2·0 or greater and those with T-scores of less 
than –2·0. Our result underscores the idea that osteoporotic patients with breast cancer 
should have the opportunity offered by aromatase inhibitors for improvement of breast 
cancer survival.
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Figure 1. Patient recruitment and analysis
n/N=number of patients who had assessment/number of patients still on study. DEXA=dual-
energy x-ray absorptiometry. *Did not meet eligibility criteria, but were still included in 
analyses.
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Figure 2. Individual patient change of bone mineral density by treatment group for patients with 
assessments at baseline, 1 years, and 2 years
For patients with T-scores –2·0 or greater at baseline (A) and patients with T-scores less 
than –2·0 at baseline (B).
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Table 1
Baseline characteristics
Baseline T-score-2-0 or greater Baseline T-score less than-2-0
Exemestane (n=147) Anastrozole (n=153) Exemestane (n=101) Anastrozole (n=96)
Age at allocation (years)
    40-49 4 (3%) 4 (3%) 1 (1%) 0 (0%)
    50-59 50 (34%) 59 (39%) 21 (21%) 15 (16%)
    60-69 52 (35%) 63 (41%) 37 (37%) 28 (29%)
    70-79 34 (23%) 17 (11%) 31 (31%) 42 (44%)
    ≥80 7 (5%) 10 (7%) 11 (11%) 11 (11%)
Median age (IQR; years) 63.2 (58.1-70.9) 62.0 (57.1-68.2) 68.3 (61.1-73.7) 71.0 (61.9-77.0)
Ethnic origin
    Data missing 0 (0%) 2 (1%) 3 (3%) 3 (3%)
    White 141 (96%) 141 (92%) 90 (89%) 86 (90%)
    Black 4 (3%) 7 (5%) 4 (4%) 3 (3%)
    Asian 1 (1%) 1 (1%) 4 (4%) 3 (3%)
    Unknown 1 (1%) 2 (1%) 0 (0%) 1 (1%)
ECOG performance status score
    0 (fully) 130 (88%) 136 (89%) 75 (74%) 76 (79%)
    1 (restricted) 15 (10%) 17 (11%) 23 (23%) 20 (21%)
    ≥2 (ambulatory) 2 (1%) 0 (0%) 3 (3%) 0 (0%)
Postmenopausal status
    Bilateral oophorectomy 11 (7%) 14 (9%) 2 (2%) 7 (7%)
    Age ≥60 years 89 (61%) 88 (58%) 79 (78%) 77 (80%)
    Age 45-59 years (<12 months since last 
menstruation; hysterectomy)
5 (3%) 9 (6%) 2 (2%) 2 (2%)
    45-59 years (>12 months) 41 (28%) 40 (26%) 17 (17%) 10 (10%)
    45-59 (<12 months; HRT) 1 (1%) 2 (1%) 1 (1%) 0 (0%)
Type of most extensive primary surgery
    Partial mastectomy 111 (76%) 113 (74%) 61 (60%) 55 (57%)
    Mastectomy (not otherwise specified) 36 (24%) 40 (26%) 40 (40%) 41 (43%)
Axillary dissection
    No 95 (65%) 89 (58%) 57 (56%) 55 (57%)
    Yes 52 (35%) 64 (42%) 44 (44%) 41 (43%)
Tumour laterality
    Bilateral 1 (1%) 0 (0%) 0 (0%) 0 (0%)
    Left 77 (52%) 83 (54%) 59 (58%) 52 (54%)
    Right 69 (47%) 70 (46%) 42 (42%) 44 (46%)
Oestrogen-receptor status
    Negative 1 (1%) 1 (1%) 0 (0%) 1 (1%)
    Positive 146 (99%) 152 (99%) 101 (100%) 95 (99%)
Progesterone-receptor status
    Negative 18 (12%) 25 (16%) 19 (19%) 22 (23%)
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Baseline T-score-2-0 or greater Baseline T-score less than-2-0
Exemestane (n=147) Anastrozole (n=153) Exemestane (n=101) Anastrozole (n=96)
    Positive 129 (88%) 128 (84%) 82 (81%) 74 (77%)
T stage
    T1 113 (77%) 115 (75%) 67 (66%) 72 (75%)
    T2 29 (20%) 33 (22%) 30 (30%) 22 (23%)
    T3 5 (3%) 5 (3%) 3 (3%) 2 (2%)
    TX 0 (0%) 0 (0%) 1 (1%) 0 (0%)
N stage
    N0 117 (80%) 112 (73%) 71 (70%) 67 (70%)
    N1 21 (14%) 30 (20%) 26 (26%) 22 (23%)
    N2 7 (5%) 7 (5%) 2 (2%) 3 (3%)
    N3 0 (0%) 1 (1%) 0 (0%) 2 (2%)
    NX 2 (1%) 3 (2%) 2 (2%) 2 (2%)
Previous adjuvant chemotherapy
    No 101 (69%) 97 (63%) 73 (72%) 73 (76%)
    Yes 46 (31%) 56 (37%) 28 (28%) 23 (24%)
Previous raloxifene treatment
    No 143 (97%) 152 (99%) 99 (98%) 94 (98%)
    Yes 2 (1%) 1 (1%) 2 (2%) 2 (2%)
    Unknown 2 (1%) 0 (0%) 0 (0%) 0 (0%)
Radiotherapy (previous or concurrent)
    Unknown or missing data 1 (1%) 0 (0%) 1 (1%) 1 (1%)
    Yes 115 (78%) 115 (75%) 63 (62%) 54 (56%)
    No 31 (21%) 38 (25%) 37 (37%) 41 (43%)
Fractures within 10 years before allocation?
    No 130 (88%) 143 (93%) 91 (90%) 79 (82%)
    Yes 17 (12%) 10 (7%) 10 (10%) 17 (18%)
Cardiovascular history
    None 55 (37%) 58 (38%) 52 (51%) 47 (49%)
    Ischaemia 92 (63%) 95 (62%) 49 (49%) 49 (51%)
Median bone mineral density index T-score (IQR)
    Hip −0.1 (−0.8 to 0.6) −0.4 (−0.9 to 0.5) −1.9 (−2.5 to −1.3) −1.8 (−2.3 to −1.3)
    Lumbar spine −0.1 (−0.9 to 0.9) −0.2 (−1.0 to 0.6) −2.3 (−2.8 to −1.7) −2.4 (−2.7 to −2.1)
Bisphosphonate use
    No 145 (99%) 148 (97%) 5 (5%) 5 (5%)
    Yes 2 (1%) 5 (3%) 96 (95%) 91 (95%)
Data are n (%), unless stated otherwise. ECOG=Eastern Cooperative Oncology Group. HRT=hormone replacement treatment.
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Table 2
Relative change of patients' bone mineral density from baseline
Exemestane Anastrozole p value
*
N Mean % change (95% CI) N Mean % change (95% CI)
At 2 years
Hip
    Baseline T-score ≥−2.0 83 −1.93% (−2.93 to −0.93) 80 −2.71% (−4.32 to −1.11) 0.10
    Baseline T-score <−2.0 61 2.09% (−1.45 to 5.63) 55 0.00% (−3.67 to 3.66) 0.28
Lumbar spine
    Baseline T-score ≥−2.0 87 −0.92% (−2.35 to 0.50) 77 −2.39% (−3.77 to −1.01) 0.08
    Baseline T-score <−2.0 63 2.11% (−0.84 to 5.06) 57 3.72% (1.54 to 5.89) 0.26
At 1 year
Hip
    Baseline T-score ≥−2.0 99 −0.62% (−1.48 to 0.23) 114 −1.66% (−2.73 to −0.59) 0.01
    Baseline T-score <−2.0 64 0.61% (−1.81 to 3.04) 66 0.83% (−0.16 to 1.82) 0.23
Lumbar spine
    Baseline T-score ≥−2.0 102 −0.59% (−1.73 to 0.54) 116 −1.88% (−3.06 to −0.70) 0.32
    Baseline T-score <−2.0 69 3.75% (2.13 to 5.36) 66 2.60% (1.24 to 3.96) 0.67
*
Based on two-sided Student's t test of individual patient change.
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Table 3
Absolute change of patients' T-scores from baseline
Exemestane Anastrozole p value
*
N Mean % change (95% CI) N Mean % change (95% CI)
At 2 years
Hip
    Baseline T-score ≥−2.0 83 −0.16 (−0.29 to −0.03) 80 −0.16 (−0.27 to −0.05) 0.98
    Baseline T-score <−2.0 61 0.12 (−0.06 to 0.31) 55 0.01 (−0.19 to 0.21) 0.41
Lumbar spine
    Baseline T-score ≥−2.0 87 −0.11 (−0.24 to 0.03) 77 −0.20 (−0.34 to −0.06) 0.35
    Baseline T-score <−2.0 63 0.17 (−0.02 to 0.36) 57 0.24 (0.07 to 0.41) 0.61
At 1 year
Hip
    Baseline T-score ≥−2.0 97 −0.03 (−0.13 to 0.07) 111 −0.12 (−0.21 to −0.04) 0.18
    Baseline T-score <−2.0 61 0.04 (−0.10 to 0.80) 66 0.05 (0.00 to 0.11) 0.89
Lumbar spine
    Baseline T-score ≥−2.0 99 −0.08 (−0.18 to 0.02) 111 −0.21 (−0.33 to −0.09) 0.11
    Baseline T-score <−2.0 69 0.29 (0.17 to 0.40) 66 0.18 (0.08 to 0.28) 0.18
*
Based on two-sided Student's t test of individual patient change.
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Table 4
Changes in biomarkers of bone turnover between baseline and 1 year




    Baseline 13.6% (12.9-14.3) 13.7% (13.1-14.4) ..
    1 year 14.9% (13.9-15.9) 14.9% (14.9-15.8) 0.96
T-score ≤−2.0 (n=81)
    Baseline 15.0% (14.1-16.0) 15.1% (14.1-16.2) ..
    1 year 10.5% (9.6-11.4) 10.5% (9.7-11.3) 0.31
PINP
T-score >−2.0 (n=117)
    Baseline 52.9% (48.9-57.3) 52.3% (48.4-56.6) ..
    1 year 58.4% (53.5-63.7) 54.5% (49.7-59.8) 0.61
T-score ≤−2.0 (n=81)
    Baseline 58.2% (53.2-63.7) 57.3% (51.8-63.3) ..
    1 year 30.9% (26.3-36.3) 28.7% (25.2-32.7) 0.12
Data are mean percentage change (95% CI).
*
Based on two-sided Student's t test of patient change.
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